Foamix, a specialty pharmaceutical company, and LEO Pharma have entered into a settlement and license agreement with an affiliate of Teva to resolve pending patent litigation involving Finacea Foam.
Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam 15% for the topical treatment of inflammatory papules and pustules of mild to moderate ...
DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug ...
Azelaic acid 15%; foam; contains propylene glycol. Monitor patients with dark complexions for hypopigmentation. Discontinue if sensitivity or severe irritation develops. Avoid eyes, mouth, other ...
BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing ...
HealthDay News — The FDA has approved a new prescription treatment for rosacea. Finacea (azelaic acid) Foam, 15%, has been approved for the topical treatment of mild to moderate rosacea, according to ...
The first commercial product developed for the American market by Israeli biotech start-up Foamix has received FDA approval, the company announced last week. Finacea Foam, a 15% solution of azelaic ...
* FDA approves Bayer's Finacea (azelaic acid) foam for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results